Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
This Phase III, randomized, double-blind, parallel-grouped, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab in maintenance of remission in participants with moderately to severely active UC who are naive to TNF inhibitors and refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment.
Inclusion Criteria:
Exclusion Criteria:
Chicago, Illinois 60611, United States
Chapel Hill, North Carolina 27599, United States
Halifax, Nova Scotia B3H 1V7, Canada
Hanover, 30625, Germany
Hyderabad, Andhra Pradesh 500012, India
Hyderabad, Andhra Pradesh 500058, India
Belagavi, Karnataka 590010, India
Beer Yaacov, 6093000, Israel
Uzhhorod, 88009, Ukraine